Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

Rosen, 1993, Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis, Nature, 362, 59, 10.1038/362059a0 DeJesus-Hernandez, 2011, Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked frontotemporal dementia and amyotrophic lateral sclerosis, Neuron, 72, 245, 10.1016/j.neuron.2011.09.011 Renton, 2011, A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD, Neuron, 72, 257, 10.1016/j.neuron.2011.09.010 D'Amico, 2013, Clinical perspective of oxidative stress in sporadic ALS, Free Radic Biol Med, 65, 509, 10.1016/j.freeradbiomed.2013.06.029 Garbuzova-Davis, 2011, Amyotrophic lateral sclerosis: A neurovascular disease, Brain Res, 1398, 113, 10.1016/j.brainres.2011.04.049 Mitsumoto, 2008, Oxidative stress biomarkers in sporadic ALS, Amyotroph Lateral Scler, 9, 177, 10.1080/17482960801933942 Simpson, 2004, Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden, Neurology, 62, 1758, 10.1212/WNL.62.10.1758 Sohmiya, 2005, An increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patients, J Neurol Sci, 228, 49, 10.1016/j.jns.2004.09.030 Murata, 2008, Increased mitochondrial oxidative damage in patients with sporadic amyotrophic lateral sclerosis, J Neurol Sci, 267, 66, 10.1016/j.jns.2007.09.038 Beal, 1997, Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis, Ann Neurol, 42, 644, 10.1002/ana.410420416 Watanabe, 1994, Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions, J Pharmacol Exp Ther, 268, 1597 Kawai, 1997, Effects of a novel free radical scavenger, MCI-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model, J Pharmacol Exp Ther, 281, 921 Ito, 2008, Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice, Exp Neurol, 213, 448, 10.1016/j.expneurol.2008.07.017 2003, Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters, Cerebrovasc Dis, 15, 222, 10.1159/000069318 Cedarbaum, 1999, The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function, J Neurol Sci, 169, 13, 10.1016/S0022-510X(99)00210-5 Ohashi, 2001, Study of functional rating scale for amyotrophic lateral sclerosis: revised ALSFRS(ALSFRS-R) Japanese version, No To Shinkei, 53, 346 Yoshino, 2006, Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study), Amyotroph Lateral Scler, 7, 241, 10.1080/17482960600881870 Abe, 2014, Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients, Amyotroph Lateral Scler Frontotemporal Degener, 15, 610, 10.3109/21678421.2014.959024 Brooks, 2000, El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis, Amyotroph Lateral Scler Other Motor Neuron Disord, 1, 293, 10.1080/146608200300079536 Bensimon, 1994, A controlled trial of riluzole in amyotrophic lateral sclerosis, N Engl J Med, 330, 585, 10.1056/NEJM199403033300901 Norris, 1974, The administration of guanidine in amyotrophic lateral sclerosis, Neurology, 24, 721, 10.1212/WNL.24.8.721 Oda, 1996, Reliability and factorial structure of a rating scale for amyotrophic lateral sclerosis, No To Shinkei, 48, 999 Jenkinson, 1999, Evidence for the validity and reliability of the ALS assessment questionnaire: the ALSAQ-40, Amyotroph Lateral Scler Other Motor Neuron Disord, 1, 33, 10.1080/146608299300080022 Yamaguchi, 2004, Validity and clinical applicability of the Japanese version of amyotrophic lateral sclerosis—assessment questionnaire 40 (ALSAQ-40), No To Shinkei, 56, 483 2010 2010 Paolo Messina, Ettore Beghi. Modeling drop-outs in amyotrophic lateral sclerosis. Contemp Clin Trials 33: 218–22. Castrillo-Viguera, 2010, Clinical significance in the change of decline in ALSFRS-R, Amyotroph Lateral Scler, 11, 178, 10.3109/17482960903093710